Literature DB >> 20191864

[Adverse reactions of different treatments in chronic hepatitis C].

Cătălina Luca1, Lucia Grigore, A Vâţă, Carmen Dorobăţ.   

Abstract

Hepatitis C virus infection is estimated to affect over 170 million people worldwide. Standard treatment for chronic HCV involves an interferon-based preparation and ribavirin for 24 to 48 weeks. These therapeutic regimens are associated with numerous adverse events, among which constitutional and neuropsychiatric symptoms, as well as hematological abnormalities, stand out. Adverse events resulting from the treatment of hepatitis C can jeopardize the quality of life of patients and their response to treatment. The control of those events involves medicinal and non-medicinal interventions. The latter include a reduction in the dosage of IFN or RBV and discontinuation of the treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20191864

Source DB:  PubMed          Journal:  Rev Med Chir Soc Med Nat Iasi        ISSN: 0048-7848


  2 in total

1.  Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey.

Authors:  M Assem; M Yousri
Journal:  Int J Hepatol       Date:  2011-05-14

2.  Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Authors:  Shinya Sato; Kei Moriya; Masanori Furukawa; Soichiro Saikawa; Tadashi Namisaki; Mitsuteru Kitade; Hideto Kawaratani; Kosuke Kaji; Hiroaki Takaya; Naotaka Shimozato; Yasuhiko Sawada; Kenichiro Seki; Koh Kitagawa; Takemi Akahane; Akira Mitoro; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  Clin Mol Hepatol       Date:  2019-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.